Is Nintedanib available in the country?

Nintedanib (Nintedanib) has been approved by the State Food and Drug Administration in 2022 for domestic marketing, and subsequently entered Class B medical insurance through relevant policies of the National Medical Insurance Administration, limited to idiopathic pulmonary fibrosis Patients with interstitial lung disease (IPF) or systemic sclerosis-related interstitial lung disease (SSc-ILD) will be reimbursed. The generic name is nintedanib ethanesulfonate soft capsules. Specifications: 150mg*30 capsules. The price per box may be more than 4,000 yuan. Nintedanib belongs to the tyrosine kinase inhibitor class of drugs and is used to treat idiopathic pulmonary fibrosis. It helps prevent changes in lung tissue. It is also used to treat chronic (long-term) interstitial lung disease, in which pulmonary fibrosis continues to develop or worsen. This drug is also used to slow the decline in lung function in people with interstitial lung disease associated with systemic sclerosis.